Table 2.
Total | Cytoplasmic expression | Nuclear expression | |||||||
---|---|---|---|---|---|---|---|---|---|
− | + | ++ | ≧+ | % | − | + | % | ||
76 | 14 | 40 | 22 | 62/76 | 82 | 44 | 32 | 42 | |
FIGO stage | |||||||||
I | 37 | 7 | 16 | 14 | 30/37 | 81 | 20 | 17 | 46 |
II | 10 | 3 | 5 | 2 | 7/10 | 70 | 6 | 4 | 40 |
III | 24 | 3 | 17 | 4 | 21/24 | 88 | 15 | 9 | 38 |
IV | 5 | 1 | 2 | 2 | 4/5 | 80 | 3 | 2 | 40 |
Histology | |||||||||
Serous | 27 | 5 | 14 | 8 | 22/27 | 82 | 16 | 11 | 41 |
Mucinous | 7 | 3 | 3 | 1 | 4/7 | 57 | 5 | 2 | 29 |
Endometrioid | 17 | 2 | 9 | 6 | 15/17 | 88 | 11 | 6 | 35 |
Clear cell | 25 | 4 | 14 | 7 | 21/25 | 84 | 12 | 13 | 52 |
Cytoplasmic immunostaining was estimated as follows: −, 0% positive cells; +, 1–50% positive cells; ++, >50% positive cells.
Nuclear immunostaining was classified as follows: −, absence of tumor cells with nuclear staining; +, presence of tumor cells with nuclear staining.